Gamma Medica to Present at 2017 TPP Healthcare China Partnering Forum; in Conjunction with Biotech Showcase alongside JP Morgan Healthcare Conference

Forum aligns global investors and CEOs

SAN FRANCISCO--()--Gamma Medica, Inc.


Philip Croxford, President and CEO of Gamma Medica, will be presenting at 2017 TPP Healthcare China Forum Cancer Diagnostics panel in conjunction with Biotech Showcase and alongside the JP Morgan Healthcare Conference.


Editor’s Note: 1:1 interviews with Phil Croxford are available on request.


Mr. Croxford will be discussing the clinical advantages and advancements of Gamma Medica’s LumaGEM® Molecular Breast Imaging (MBI) system, the company’s recent global expansion and the future corporate strategy.



Panel Therapeutic Area: Women's health: Monday, January 9, 2017; 10:00-11:00am PST

Panel Therapeutic Area: Cancer Diagnostics: Tuesday, January 10, 2017; 9:00-10:00am PST



Hilton Hotel, 55 Cyril Magnin St., San Francisco, CA 94102

Room Embarcadero, 3rd floor, Parc 55


Gamma Medica recently announced growth across the U.S., with global expansion set for 2017 to bring its LumaGEM (MBI) system to more leading health care facilities, giving women critical access to accurate secondary breast cancer screenings options. This growth coincides with the company’s educational Be Certain campaign, aiming to eliminate myths and raise awareness about the facts on breast cancer detection and breast health. Detecting breast cancer in dense breast tissue (affecting 50 percent of U.S. women) can be like looking for a snowflake in a snowstorm, as dense tissue and cancerous growths both show white on mammograms, as well as yield high false positives via other common screening methods. Molecular imaging technology is changing that, so every woman – no matter her breast density – can get a fair and accurate diagnosis. Secondary screenings are an important part of early breast cancer detection. MBI was specifically designed to detect cancer in dense breast tissue.


About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer, with women who have dense breast tissue. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information, visit,


Racepoint Global
Tara Kadioglu, 617-624-3239


Racepoint Global
Tara Kadioglu, 617-624-3239